• Prof.ssa Désirée Deandreis (Professore Associato, Responsabile del Progetto)
• Dott.ssa Virginia Liberini (PhD Student)
• Dott.ssa Giulia Polverari (PhD Student)
• Dott.ssa Elena Califaretti (Specializzanda)
• Dott.ssa Sara Dall’Armellina (Specializzanda)

• SC Medicina Nucleare U, Palazzina Ciocatto, AOU Città della Salute e della Scienza, Presidio Molinette (Piano terra) - C.so Dogliotti 14, Torino 10126
• Email: deandreis@unito.it/ deandreisde@gmail.com
• Tel: +39 011 6336173   Fax: +39 0116335019

• Prof.ssa Désirée Deandreis

• Functional Imaging PET/CT and SPECT/CT in oncology, neurology and cardiometabolic system;
• Radiometabolic Treatment: Radioactive Iodine for benign thyroid disease, transarterial radioembolization (TARE), Radium 223;
• Specific research in Oncological Diseases: Thyroid Cancer, Neuroendocrine Tumors, Prostate Cancer, Melanoma and other solid tumors;
• Molecular imaging (68Ga- DOTATOC, 68Ga PSMA-1, 18F-Amyloid PET/CT);
• Development of methodological approach for Radiomic and Artificial Intelligence in Molecular Imaging;
• Anthropomorphic phantom and synthetic tumoural Models development by 3D Printer.

Pubblicazioni - ultimi 3 anni (Prof.ssa Désirée Deandreis)

1. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Deandreis D, Guarneri A, Ceci F, Lillaz B, Bartoncini S, Oderda M, Nicolotti DG, Pilati E, Passera R, Zitella A, Bellò M, Parise R, Carlevato R, Ricardi U, Gontero P. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815. Doi: 10.1007/s00259-020-04809-8.
2. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D. Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1772-1780. doi: 10.1007/s00259-018-4018-z.
3. Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer. Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle MR. J Nucl Med. 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606.
4. Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG,  Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.
5. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E; Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. N Engl J Med. 2012 May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586.

• 2020 PET Thyroid TKI (NP 528/2020): Predictive value of volumetric parameters at baseline ¹⁸F-FDG-PET/CT of response to Lanvatinib in patient with radioactive iodine refractory thyroid tumors. Multicentric, Italy (PI)
• 2020 “Studio multicentrico AIMN ITA-IMMUNO-PET (Italian Immunotherapy PET study)”. Role of FDG PET/CT in prediction and assessment of response to immunotherapy in solid neoplasms. Co-PI
• 2019 Research Grant by CRT (Cassa di Risparmio di Torino) Foundation: Radiomics Analysis in the evaluation of NeuroEndocrine Tumors (NET) in Nuclear Medicine. An innovative methodology to investigate tumor heterogeneity. 
• Research Grant by Department of Medical Sciences, University of Turin (RILO 2018-2020). Project:” Role of FDG PET/CT in the evaluation of response to therapy with tyrosine kinase inhibitors (TKIs) in thyroid cancer. Monocentric Study, Città della Salute e della Scienza hospital, University of Turin.
• Research Grant by Department of Medical Sciences, University of Turin (RILO 2017-2019). Project: “Ga68 DOTATOC PET/CT as a new prognostic tool and predictive value of response to treatment in metastatic Neuroendocrine Tumor”, Monocentric Study Città della Salute e della Scienza hospital, Turin.
• 2017: EuBI-NodoIM-TO project (Italian Euro-BioImaging Network in Molecular Imaging). PI Prof Enzo Terreno, Department of Molecular Biotechnology and Health Sciences, University of Turin
• 2016: P-5315. Grant: Città della Salute e della Scienza Hospital. PSMA PET /CT in the evaluation of prostate cancer recurrence (P.I. Prof P. Gontero). Monocenter prospective study, Città della Salute e della Scienza Hospital of Turin.
• Furthermore our Unit is involved in more than 40 trials including PET/CT as a tool for the evaluation of efficacy of experimental drugs in oncology and in neurology.